首页> 外文期刊>nephrology dialysis transplantation >Angiotensin-converting enzyme inhibition and the combination of a beta blocker and a diuretic are equally effective in lowering proteinuria in patients with glomerulonephritis
【24h】

Angiotensin-converting enzyme inhibition and the combination of a beta blocker and a diuretic are equally effective in lowering proteinuria in patients with glomerulonephritis

机译:血管紧张素转换酶抑制以及 β 受体阻滞剂和利尿剂的联合用药在降低肾小球肾炎患者的蛋白尿方面同样有效

获取原文

摘要

In this study we compared the antihypertensive and antiproteinuric efficacies of an angiotensin-converting enzyme inhibitor and of conventional treatment consisting of a beta blocker and a diuretic in 13 patients with biopsy-proven glomerulonephritis and a proteinuria of more than 2 g/24 h. Ten of these 13 patients were normotensive. None had diabetes mellitus. In a randomized cross-over design with two treatment periods of 6 weeks, each preceded by a washout period of 4 weeks, patients were treated with benazepril (20 mg o.d.) and the combination of metoprolol (200 mg o.d.) and chlorthalidone (25 mg o.d.). At the end of the treatment periods with benazepril or metoprolol/chlorthalidone mean arterial pressure was lowered to a similar degree by 7.4 (mean, 95confidence interval 2.0–12.7) and 9.7 (5.7–13.7) mmHg respectively. Both treatment modalities caused similar reductions in proteinuria, being 3.4 g/24 h (mean, 95confidence interval 2.1–4.8) on benazepril and 3.2 (1.2–5.1) g/24 h on metoprolol/chlorthalidone. Glomerular filtration rate and renal plasma flow were slightly less during metoprolol/chlorthalidone treatment. Subgroup analysis of normotensive patients gave similar results.In conclusion, in these patients with glomerular disease angiotensin-converting enzyme inhibition was not more effective than the conventional treatment with the combination of a beta blocker and a diuretic in reducing blood pressure and proteinuria. Both treatments reduced proteinuria not only in hypertensive, but also in normotensive p
机译:在这项研究中,我们比较了血管紧张素转换酶抑制剂和由 β 受体阻滞剂和利尿剂组成的常规治疗在 13 例活检证实的肾小球肾炎和蛋白尿超过 2 g/24 小时的患者中的抗高血压和抗蛋白尿疗效。这 13 例患者中有 10 例血压正常。没有人患有糖尿病。在随机交叉设计中,两个治疗期为 6 周,每个治疗期前有 4 周的清除期,患者接受贝那普利(20 mg 外表)和美托洛尔(200 mg 外表)和氯噻酮(25 mg外表)的组合治疗。在贝那普利或美托洛尔/氯噻酮治疗期结束时,平均动脉压分别降低 7.4(平均 95% 置信区间 2.0-12.7)和 9.7 (5.7-13.7) mmHg。两种治疗方式均导致蛋白尿减少相似,贝那普利组为3.4 g/24 h(平均值,95%置信区间为2.1-4.8),美托洛尔/氯噻酮组为3.2(1.2-5.1)g/24 h。美托洛尔/氯噻酮治疗期间肾小球滤过率和肾血浆流量略低。对血压正常的患者进行亚组分析得出了类似的结果。总之,在这些肾小球疾病患者中,血管紧张素转换酶抑制在降低血压和蛋白尿方面并不比β受体阻滞剂和利尿剂联合使用的常规治疗更有效。两种治疗不仅降低了高血压患者的蛋白尿,而且降低了血压正常的 p

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号